Creative Planning Has $700,000 Stake in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Creative Planning boosted its stake in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 100.3% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 5,389 shares of the medical instruments supplier’s stock after buying an additional 2,698 shares during the period. Creative Planning’s holdings in Mesa Laboratories were worth $700,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Louisiana State Employees Retirement System boosted its stake in Mesa Laboratories by 4.0% in the 2nd quarter. Louisiana State Employees Retirement System now owns 2,600 shares of the medical instruments supplier’s stock valued at $226,000 after buying an additional 100 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Mesa Laboratories by 6.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,873 shares of the medical instruments supplier’s stock valued at $316,000 after purchasing an additional 175 shares during the last quarter. EntryPoint Capital LLC raised its position in Mesa Laboratories by 35.2% in the 1st quarter. EntryPoint Capital LLC now owns 741 shares of the medical instruments supplier’s stock valued at $81,000 after purchasing an additional 193 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in Mesa Laboratories in the 2nd quarter valued at $26,000. Finally, BNP Paribas Financial Markets raised its position in Mesa Laboratories by 4.5% in the 1st quarter. BNP Paribas Financial Markets now owns 7,565 shares of the medical instruments supplier’s stock valued at $830,000 after purchasing an additional 327 shares during the last quarter. Institutional investors and hedge funds own 90.60% of the company’s stock.

Insider Buying and Selling

In related news, SVP Brian David Archbold sold 1,499 shares of Mesa Laboratories stock in a transaction on Friday, September 13th. The stock was sold at an average price of $125.00, for a total transaction of $187,375.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, SVP Brian David Archbold sold 1,499 shares of Mesa Laboratories stock in a transaction on Friday, September 13th. The stock was sold at an average price of $125.00, for a total transaction of $187,375.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Gary M. Owens sold 2,518 shares of Mesa Laboratories stock in a transaction on Monday, October 28th. The stock was sold at an average price of $113.62, for a total value of $286,095.16. Following the sale, the chief executive officer now directly owns 45,888 shares of the company’s stock, valued at approximately $5,213,794.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.40% of the stock is owned by insiders.

Mesa Laboratories Trading Up 3.5 %

MLAB stock opened at $118.00 on Monday. The company has a market cap of $638.38 million, a P/E ratio of -2.54 and a beta of 0.87. Mesa Laboratories, Inc. has a twelve month low of $82.86 and a twelve month high of $141.17. The company has a quick ratio of 1.37, a current ratio of 1.94 and a debt-to-equity ratio of 1.38. The business has a fifty day moving average of $126.08 and a 200-day moving average of $114.05.

Mesa Laboratories (NASDAQ:MLAB) last released its earnings results on Monday, August 5th. The medical instruments supplier reported $2.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.74 by $0.55. The company had revenue of $58.17 million during the quarter, compared to the consensus estimate of $55.90 million. Mesa Laboratories had a positive return on equity of 18.95% and a negative net margin of 111.89%. As a group, equities research analysts expect that Mesa Laboratories, Inc. will post 7.91 EPS for the current year.

Mesa Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Friday, November 29th will be paid a dividend of $0.16 per share. The ex-dividend date is Friday, November 29th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.54%. Mesa Laboratories’s dividend payout ratio (DPR) is presently -1.38%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on MLAB shares. StockNews.com upgraded Mesa Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, October 26th. Wells Fargo & Company started coverage on Mesa Laboratories in a research report on Tuesday, August 27th. They issued an “underweight” rating and a $120.00 price objective for the company. Finally, Evercore ISI boosted their target price on Mesa Laboratories from $120.00 to $160.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.